[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome].
Hand-foot syndrome (HFS) is a rare adverse reaction to oral fluoropyrimidine TS-1, which contains the dihydropyrimidine dehydrogenase (DPD) inhibitor. We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration. Those symptoms improved with the administration of vitamin B6, topical emollient therapy, and so on. We thought that the continuous elevation of serum 5-FU concentration, due to the accumulation of DPD inhibitor from the renal dysfunction, led to the development of HFS, although the participation of 5-FU metabolites such as F-beta-alanine cannot be ruled out.
Arai
Kuniyoshi
K
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Iwasaki
Yoshiaki
Y
Kimura
Yutaka
Y
Takahashi
Keiichi
K
Yamaguchi
Tatsuro
T
Honma
Shigenori
S
Takahashi
Toshio
T
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003231:Conjunctivitis / Q000139:chemically induced; D004338:Drug Combinations; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D010094:Oxonic Acid / Q000009:adverse effects*; D011355:Prodrugs / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013280:Stomatitis / Q000139:chemically induced; D013577:Syndrome; D005641:Tegafur / Q000009:adverse effects*; D025101:Vitamin B 6 / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011355:Prodrugs; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D025101:Vitamin B 6